We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Medical Center Collaborates with GenomeQuest

By LabMedica International staff writers
Posted on 14 Jan 2013
GenomeQuest, Inc. More...
(Westborough, MA, USA) a leader in sequence data management, and Beth Israel Deaconess Medical Center (BIDMC; Boston, MA, USA), a Harvard Medical School teaching hospital, are entering into a two-year collaboration to develop whole-genome analysis (WGA) applications for personalized health care. The announcement was made during the opening session of the World Health Forum, held at Harvard Medical School, on December 20, 2012, in Boston (MA, USA).

GenomeQuest will provide whole-genome data management and analysis capabilities for all next-generation sequencing projects in BIDMC’s dept. of pathology. GenomeQuest will also provide application programming interface (API) access and training to the department’s scientific investigators and applied mathematicians. BIDMC pathologists will develop clinical grade annotation methods and databases for diagnoses of cancers and other diseases. Collaborative projects will span user interface, workflows, sequence, and annotation management, and integration into health care Information Technology (IT) systems.

“The latest PriceWaterHouseCoopers report on personalized medicine estimates that this market will grow to nearly $500 billion in 2015 and terms it a ‘disruptive innovation’ for life sciences,” explained BIDMC chief of pathology Jeffrey Saffitz, MD, PhD. “The BIDMC pathology department is already a national leader in the development and application of genomics for personalized medicine, having launched its Genomic Medicine Training Initiative one year ago, and, this past spring, issuing a ‘Call to Action’ for pathology training programs across North America to do the same. Our collaboration with GenomeQuest helps provide us with the infrastructure to continue this work.”

Beth Israel Deaconess Medical Center is clinically affiliated with the Joslin Diabetes Center and is a research partner of the Dana-Farber/Harvard Cancer Center. The core technology of GenomeQuest is the GQ-Engine–a sequence database engine that is purpose-built for storing, managing, and analyzing sequence data at whole- and multigenome scale.

Related Links:
GenomeQuest, Inc.
Beth Israel Deaconess Medical Center


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
PSA Assay
CanAg PSA EIA
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.